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ABSTRACT 
 
Introduction: Detecting early cardiac involvement in Fabry disease (FD) is important 
because therapy may alter disease progression. Cardiovascular magnetic resonance 
(CMR) can detect T1 lowering, representing myocardial sphingolipid storage. In 
many diseases, early mechanical dysfunction may be detected by abnormal global 
longitudinal strain (GLS). We explored the relationship of early mechanical 
dysfunction and sphingolipid deposition in FD. 
Methods: An observational study of 221 FD and 77 healthy volunteers (HV) who 
underwent CMR (LV volumes, mass, native T1, GLS, late gadolinium enhancement), 
ECG, and blood biomarkers, as part of the prospective multicenter Fabry400 study. 
Results: All FD had normal LV ejection fraction (EF 738%). Mean indexed LV 
mass (LVMi) was 89±39g/m2 in FD and 55.6±10g/m2 in HV. 102 (46%) FD 
participants had left ventricular hypertrophy (LVH). There was a negative correlation 
between GLS and native T1 in FD patients (r=-0.515, p<0.05). In FD patients without 
LVH (early disease), as native T1 reduced there was a reduction in GLS (r=-0.285, 
p<0.05), but only in males and not females (males: low T1 -18.3±1.6ms vs. normal T1 
-20.0±1.0ms, p<0.05). ECG changes were not associated with impaired GLS.  
Conclusions: Fabry males have changes in myocardial deformation before the onset 
of LVH associated with sphingolipid deposition; females display mechanical 
dysfunction only once they develop LVH, supporting possible sex dimorphism in the 
early myocardial functional response to storage.  
  
KEY QUESTIONS 
 
What is already known about the subject? 
Cardiac involvement in Fabry disease is characterized by progressive LVH, 
myocardial fibrosis and heart failure. Impairment of systolic strain measured using 
speckle-tracking echocardiography has previously been described in Fabry disease. 
CMR imaging with T1 mapping can identify cardiac involvement earlier in the 
disease process, however, there is only limited data investigating the relationship 
between myocardial strain and sphingolipid deposition.  
 
What does this study add? 
This is the first study evaluating T1 mapping and myocardial systolic strain using 
CMR feature-tracking in a large cohort of patients with Fabry disease. It shows that 
Fabry males have impaired myocardial deformation before the onset of LVH 
supporting a possible sex dimorphism in the early myocardial functional response to 
storage.  
 
How might this impact on clinical practice? 
This study highlights that CMR feature-tracking is a sensitive imaging biomarker that 
is able to identify myocardial mechanical changes in the early stages of cardiac Fabry 
disease.  
INTRODUCTION 
 
Fabry disease (FD) is a X-linked lysosomal storage disorder caused by mutations in 
the gene (GLA) encoding for α-galactosidase A. The progressive accumulation of 
complex sphingolipids, predominantly globotriaosylceramide1 affects multiple 
organs, including the heart where it results in left ventricular hypertrophy (LVH), 
progressive cardiomyopathy, myocardial fibrosis and arrhythmias.2 Cardiac 
involvement is a major contributor to morbidity and mortality in FD.3 Evidence 
suggests that best outcomes may occur with early initiation of enzyme replacement 
therapy (ERT).4 Early cardiac involvement is difficult to detect and the identification 
of early phenotypic markers is required. Change in myocardial deformation – systolic 
strain – offers potential. Impairment of global longitudinal strain (GLS) has been 
described in FD using speckle tracking echocardiography in those with and without 
LVH.5,6,7 Impaired GLS precedes any reduction in ejection fraction and is linked to 
worse functional status.8 
 
Cardiovascular magnetic resonance (CMR) imaging can quantify myocardial strain 
using feature-tracking (FT-CMR) but there is a paucity of knowledge regarding its 
application in FD. We aimed to determine whether early storage (low T1 measured 
using T1 mapping) would alter myocardial contractility (measured using FT-CMR) 
before the development of LV hypertrophy. Additionally, we aimed to evaluate if 
electrical abnormalities (detected on the 12-lead ECG) alter with cardiac contractility 
during this earlier phase of the disease process.  
 
 
 
METHODS 
Study Population 
Participants were recruited from four Fabry clinics as part of the prospective, 
multicenter international observational Fabry400 study (NCT03199001) - United 
Kingdom (UK): Royal Free Hospital London, National Hospital for Neurology and 
Neurosurgery London, Queen Elizabeth Hospital Birmingham; Australia: Westmead 
Hospital Sydney. The study was approved by the relevant Research Ethics 
Committees and conformed to the principles of the Helsinki Declaration. Written 
informed consent was obtained from all participants. Inclusion criteria for the FD 
cohort included: gene-positive Fabry disease and adults ≥18 years. The healthy 
volunteer controls (HV) were prospectively recruited and had no history of 
cardiovascular disease (normal health questionnaire, no cardioactive medication 
unless for primary prevention). Exclusion criteria included standard contraindications 
to CMR. All participants underwent CMR, ECG, and blood samples during the same 
study visit. High-sensitivity cardiac troponin T (UK) and I (Australia) (hs-TnT and 
hsTnI) was measured using an electrochemiluminescence-immunoassay (Roche, 
Basel, Switzerland; normal range 0-14ng/l and 0-15ng/l respectively).  
 
CMR imaging 
All participants underwent CMR at 1.5 Tesla (Avanto (UK), Aera (Australia); 
Siemens Healthcare, Erlangen, Germany) using a standard protocol including LV 
cines in short axis (SAX), 4-chamber, 2-chamber and 3-chamber views. Native T1 
mapping was performed pre-contrast on basal and mid left ventricular SAX slices 
using a shortened modified Look-Locker inversion recovery (ShMOLLI) sequence.9 
The resulting pixel by-pixel T1 color maps were displayed using a customized 12-bit 
lookup table, where normal myocardium was green, increasing T1 was red, and 
decreasing T1 was blue. Late Gadolinium enhancement (LGE) imaging was 
performed using phase sensitive inversion recovery (bolus administration of 
gadolinium 0.1 mmol/kg body weight, Gadoterate meglumine, Dotarem, Guerbet 
S.A., France) 
 
CMR analysis 
All images were centralized and analyzed using CVI42 software (Circle 
Cardiovascular Imaging Inc., Calgary, Canada). Cardiac chamber volumes and LV 
mass (LVM) (papillary muscles included in mass) were quantified on all subjects 
from a pre-contrast breath-held SAX stack of balanced steady-state free precession 
cine images, using previously described manual contouring methodologies.10 Left 
ventricular hypertrophy (LVH) was defined as increased indexed LVM on CMR 
according to age and gender matched normal reference ranges.11 Maximum wall 
thickness (MWT) was evaluated using semi-automated measurement on CVI42 
software and a value greater than 12 mm was classified as being LVH positive.  
 
Strain – Analysis of 2D global longitudinal strain (GLS) was obtained using CVI42, 
version 5.3.4. Smooth epicardial and endocardial borders were manually drawn on the 
end-diastolic frame of all long axis images (4-chamber, 2-chamber and 3-chamber 
views), and then strain (peak GLS, the most negative value during systole) was 
obtained from the applied automatic FT algorithm (example, Figure 1a). FT evaluates 
myocardial strain by utilizing a deformable 2D model and translating this onto all 2D 
cine slices selected over the entirety of the cardiac cycle. The extent of deformation is 
determined by motion of an imaginary line placed between endo- and epicardial 
boundaries, which are tracked throughout the cardiac cycle by a pre-determined 
algorithm as previously described.12,13 The accuracy of FT was confirmed manually 
for each case (by RV), and to ensure reproducibility a maximum of five operator 
corrections were performed.  
Intra-observer reproducibility was performed by observer 1 (RV) carrying out CMR 
reanalysis in random subset of 30 study patients. For inter-observer variability, 
observer 2 (BL) independently analysed a randomly determined subset of 20 CMR 
scans.  
 
Native T1 – visual inspection of T1 color maps has shown sphingolipid deposition to 
be variable within the myocardium, and consequently four regions of interest (ROI) 
were drawn in the septal and lateral LV wall at basal and mid cavity level, taking care 
to avoid the blood-myocardial boundary14 (example, Figure 1b). Since T1 is known to 
vary between field strength, acquisition technique and site, and gender (females 
typically have higher T1 than males),14 the normal ranges of T1 values were defined 
as mean ± 2 standard deviations based on site-specific healthy controls from each 
individual center (London: males mean 956±27ms, lower limit 902ms; females mean 
978±34ms, lower limit 910ms. Birmingham: males mean 947±28ms, lower limit 
890ms; females mean 958±30ms, lower limit 898ms. Sydney: males mean 947±24ms, 
lower limit 893ms; females mean 965ms±31ms, lower limit 903ms).  
 
ECG  
Abnormal ECGs included the presence of any irregularities (prolonged or shortened 
PR interval, QRS duration >120ms, the presence of LVH by Sokolow and Lyon 
criteria, T wave inversion in at least two contiguous leads, or the presence of 
ventricular ectopy).  
 
Statistical Analysis 
Statistical analyses were carried out using SPSS 22 (IBM, Armonk, NY). Continuous 
variables are expressed as mean  standard deviation, categorical as frequencies or 
percentages. Normality was checked using the Shapiro-Wilk test. Groups were 
compared using the independent-samples t-test (normally distributed variables) or the 
Mann-Whitney U test (non-normally distributed). Chi-squared testing was utilized 
when comparing proportions of a variable between two groups.  Troponin values were 
analyzed after log transformation using parametric testing. Linear regression analysis 
(stepwise backward method) was utilized to evaluate the relationship between 
multiple continuous variables and the study outcome. A p-value of <0.05 was 
considered statistically significant. Intra- and inter-observer reproducibility was 
determined by calculating mean bias and 95% confidence intervals using Bland-
Altman analyses and intra-class correlation coefficient (ICC) for absolute agreement.  
 
RESULTS 
Participant Characteristics  
There were 298 participants in total (221 FD and 77 HV). This included (155 from 
London, 37 from Birmingham, and 29 from Sydney). Baseline demographics are 
demonstrated in Table 1. The mean FD age was 45±15 years with 85 males (38.5%) 
and 136 females (61.5%). The HV population was age-matched (± 2 years) with a 
mean age of 49.4±14 years (males 51.9%). All FD had normal LVEF (738.0%). 
Mean indexed LV mass (LVMi) was 89.0±39g/m2 in FD and 55.6±10g/m2 in HV. 
MWT was significantly higher in FD compared with HV (12±5.0mm vs. 9±1.6mm 
respectively, p<0.01). There was significant correlation between LVMi and MWT in 
both groups (FD: r=0.9 and HV: r=0.7, p<0.001). 70.8% of patients had a classical 
mutation and the remaining 29.2% non-classical. There were 102 (46%) FD 
participants with LVH.  
 
Global Myocardial Strain 
Adequate tracking quality was obtained for all study participants. Left ventricular 
ejection fraction (LVEF) did not correlate with LVMi (r=0.004, p=0.9). However, 
GLS became increasingly impaired (values becoming less negative) as LVMi 
increased (r=0.728, p<0.001, Figure 2a and b). GLS was impaired in the LVH-
positive FD group compared to LVH-negatives and HV (table 2, p<0.05). This was 
similar when split by sex; however the difference was greater in the male cohort 
(table 2). Similar relationships were observed when correlating LVEF and GLS with 
MWT as a marker of myocardial hypertrophy (supplementary table 1).  
 
Myocardial Native T1 and Strain 
In the total FD cohort, 72% (n=159/221) had a low native T1 – 91% in the LVH 
positive subgroup (n=93/102) compared to 56% in the LVH negative subgroup 
(n=66/119). There was a significant negative correlation between GLS and native T1 
in the total FD cohort (r=-0.515, p<0.05) as shown in Figure 3a.  
 
LVH Negative FD Population 
There were 119 FD participants who were LVH negative when classified by LVMi 
(53.8% of total FD population). The mean age was 37±13.4 years, which was 
significantly lower than the LVH positive group (53±11.7 years, p<0.05). 81.5% of 
the LVH negative cohort were female and 68.6% had a classical mutation. Mean 
LVMi was higher in this group than in HV (62±10.4g/m2 vs. 55.6±10.1g/m2, 
p<0.05), but maximum wall thickness (MWT) was similar (8.8±1.7mm vs. 
9.0±1.6mm, p=0.5). GLS in LVH negative FD was lower (less impaired) when 
compared to HV (-20.3±2.9 and -19.3±2.0, p<0.05). When split by sex however, no 
significant differences were seen (table 2).  
In the LVH-negative FD subgroup, as native T1 reduced there was also an 
impairment in GLS (r=-0.285, p<0.05) as shown in Figure 3b. When split by sex, only 
males and not females demonstrated impairment in GLS as native T1 reduced (figure 
4, table 2). When classifying LVH by a MWT similar significant trends were 
observed (supplementary figure 1 and table 2).  
Multivariable linear regression analysis demonstrated that LVMi and GLS were both 
independent predictors of a reduction in native T1 and a reduction in GLS. This was 
found in both the total population and the LVH negative cohort (supplementary table 
3).  
 
ERT 
Of the total FD cohort 54.3% were on ERT and there was a significant difference in 
peak GLS in those taking ERT compared to those not on therapy (on ERT vs. ERT 
naïve: -17.6±3.8 vs. -19.7±2.9, p<0.01). When split by gender this difference was 
only present in the female population (female: on ERT -19.2±3.5 vs. ERT naïve -
20.4±2.5, p<0.05; male: on ERT -16.2±3.5 vs. ERT naïve -16.9±2.5, p=NS). Of the 
LVH negative cohort 36.1% were on ERT, however no significant differences in 
systolic strain were seen when compared to those not on any therapy.  
 LGE 
183 participants were given Gadolinium-based contrast agents (GBCA) and of these 
77 (34.8%) had LGE. There was a significant difference in mean GLS between FD 
with and without LGE (LGE: -17.1±3.7 vs. no LGE: -19.7±2.5, p<0.05; LGE: -
17.1±3.7 vs. HV: 19.3±2.0, p<0.05). In the LVH negative group, there were 14 out of 
84 participants who had LGE (16.7%, all females) and there was no change in mean 
GLS measured (LGE: -20.4±2.2 vs. no LGE: -20.1±2.2 vs. HV: 19.3±2.0, p=0.6).  
 
ECG 
An abnormal ECG was found in 52.9% of the FD cohort. Of this, there were 18.6% in 
the LVH negative subgroup and 34.3% in the LVH positive subgroup. In the LVH 
negative sub-group, GLS did not correlate with the presence of ECG abnormalities 
and GLS values were similar to HV (table 2). This was also the case when evaluating 
GLS split by gender and in those participants with ECG abnormalities in combination 
with a low native T1 (table 2).  
 
Biomarkers 
Of the FD population 156 (70.6%) had high sensitivity troponin measured (hsTnT or 
hsTnI), with 27.6% having an elevated level above center-specific reference ranges. 
Median troponin in the total study population was 6.0µg/L (interquartile range: 1-
31µg/L). An increasing level of troponin was associated with impairment in GLS in 
the total FD population (r=0.516, p<0.05). Of the LVH negative population 87 
patients (73.1%) had hsTnT or hsTnI measured and only five had an elevated serum 
level with all others having a value <5ug/L. No significant relationship was 
demonstrated between strain and troponin in the LVH negative group (r=0.169, 
p=0.118).  
 
Reproducibility 
Intra-observer reproducibility analysis performed following repeat evaluation of 30 
CMR scans by observer 1 (RV) demonstrated a mean absolute bias of 0.7±0.6 with an 
intra-class correlation (ICC) for single measures of 0.98 (95% CI: 0.96-0.99). 
Reproducibility biases were similar when assessing inter-observer reproducibility 
following analysis of a subset of 20 CMR scans by observer 2 (BL) – mean absolute 
bias 0.6±0.5 and ICC for single measures of 0.99 (95%CI: 0.97-1.0).  
 
DISCUSSION 
The main findings of this study include: 
1. Impaired GLS occurs in FD in the absence of reduced LVEF. The impairment in 
deformation is proportionate to an increase in LVM and storage in the overall FD 
cohort, and correlates with myocardial damage as shown by both LGE and biomarker 
evidence of cell necrosis troponin. 
2. In LVH-negative FD (early disease), impaired GLS is associated with low native 
T1 in males, but not in females, suggesting that Fabry males have mechanical 
dysfunction before the onset of LVH when there is evidence of sphingolipid 
deposition (low T1). Interestingly, females only display mechanical dysfunction once 
they have LVH. 
3. ECG changes do not follow impairment in GLS – suggesting electrical changes are 
independent of mechanical changes. This is important since a change either in 
conduction and/or mechanical function may therefore serve as triggers for 
drug/enzyme intervention. 
4. In LVH-positive FD, impaired GLS is associated with other signs of overt cardiac 
involvement namely increasing LVMi and the presence of LGE.  
 
Fabry disease affects the heart.  The obvious manifestations have been ECG 
abnormalities, hypertrophy, and, in late stage disease, impairment and thinning.21, 22 
Biomarkers are also elevated 23, 24, 25 and valve disease can be present, but the latter is 
rarely a clinically significant finding. CMR has also identified LGE in early disease, 
which characteristically affects the basal infero-lateral wall. This was initially thought 
to reflect only fibrosis; however, recent developments using advanced tissue 
characterisation with CMR parametric mapping (T1 and T2 mapping) has provided 
further insights. Native T1 is low in FD, representing sphingolipid accumulation 15, 19 
in 85% of FD with LVH, and in 40-50% of LVH-negative patients, suggesting storage 
occurs early before the establishment of hypertrophy.15, 20 When LGE is present 
without thinning, this has been shown to be associated with T2 elevation and hs-TnT 
release suggesting an inflammatory process.24 Thus, the order and processes of 
phenotype development are being pieced together.  ECG changes may precede 
echocardiographic LVH, and latest results suggest there is a pre-LVH phenotype with 
storage, ECG abnormalities, slight elevation of LV mass and LVEF clustering.16  
Here, we introduce a new biomarker of myocardial mechanical dysfunction that is 
more sensitive than the ejection fraction to early changes in myocardial performance - 
GLS. This study supports the echocardiographic literature about impaired GLS in 
overt cardiac involvement in FD (LVH-positive disease), but offers new insights into 
LVH-negative disease. We have previously shown impaired GLS by speckle tracking 
echocardiography in a small sample (n=25) of LVH-negative FD with low T1 
compared to LVH-negative with normal T1.15, 26 This current study expands on these 
findings by using a much larger cohort and is the first study to assess myocardial 
strain by CMR in conjunction with T1 mapping to show a sex difference.  
 
Sex dimorphism in the FD response to storage has been previously proposed by us in 
patients with overt disease.16 That is, in addition to apparent faster storage in 
hemizygous males, LVH positive males appear to have reduced T1 lowering with 
increasing LV mass in the LVH range – suggesting the dilution of the T1 lowering 
sphingolipid signal by the presence of triggered sarcomeric protein. A further 
example, found here is that LGE can be present in LVH negative females but rarely in 
males.17 18 Here, mechanical dysfunction appears also to have sex dimorphism with 
female LVH-negative patients tolerating storage better than males – females had 
normal GLS, whereas males had impaired GLS with T1 lowering.  The male patients 
within the LVH negative cohort all had a significantly lower T1 time compared with 
females. This may be indicative of a higher degree of sphingolipid storage within the 
myocardium of males, which is poorly tolerated; consequently leading to earlier 
functional impairment.  
 
The limitations of this study include that it is only a single time point study with no 
follow-up data, but it is multicenter with a relatively large number of participants for a 
rare disease. A further limitation is that this study is only evaluating 2D longitudinal 
strain and not 3D strain. Preliminary results included assessment of 3D 
circumferential and radial strain, both of which demonstrated similar patterns to 2D 
GLS. However, when using LV short axis images to assess 3D strain parameters in 
FD patients with LVH and cavity obliteration, there was significant impairment in 
myocardial border tracking, thus excluding a large proportion of the study cohort. 
Consequently, this study only assessed 2D GLS. Histological validation of T1 
mapping for storage is lacking and it is likely that T1 mapping will miss the earliest 
storage due to the presence of a detection threshold in this technique. Further studies 
are also required to establish whether early institution of ERT based on a low T1 or 
impaired GLS in the absence of LVH affects the development of cardiac involvement. 
 
CONCLUSIONS 
In FD with LVH, myocardial strain (measured by GLS) reduces with hypertrophy, 
storage (measured by a low T1) and scar (measured by LGE). In early disease (pre-
LVH), GLS is reduced in males and preserved in females when T1 is low, suggesting 
a possible sex difference in the myocardial functional response to storage.  
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Table 1. Participant demographics and basic CMR findings 
 
 Healthy 
volunteers Fabry Total 
Fabry 
Males 
Fabry 
Females p* 
Sample size 
(n, %) 
77 (100) 221 (100) 85 (38.5) 136 (61.5) - 
Age (y) 49.414.4 4515.0 4514.8 4415.3 NS 
LVEF (%) 70.25.6 738.0 719.0 747.2 <0.05 
LVEDV (ml) 132.128.4 13131.7 14637.3 12122.7 <0.05 
LVESV (ml) 39.611.9 3617.1 4321.0 3212.6 <0.05 
GLS -19.3±2.0 -18.5±3.6 -16.3±3.3 -19.9±3.0 <0.05 
Native T1 
(ms) 
955.2±29.9 879±64.3 838.8±51.5 904.6±58.4 <0.05 
LGE (n,%) 0 (0) 77 (100) 36 (46.8) 41 (53.2) <0.05 
LVH-positive 
(n,%) 
0 (0) 102 (100) 63 (61.8) 39 (38.2) <0.05 
LVMi (g/m2) 55.610.1 8939.3 11642.6 7124.9 <0.05 
MWT (mm) 91.6 125.0 155.1 103.8 <0.05 
 
*p-value is for Fabry male-to-female comparisons.  
 
Table legend: LVEF – left ventricular ejection fraction, LVEDV – left ventricular 
end-diastolic volume, LVESV – left ventricular end-systolic volume, GLS – global 
longitudinal strain, LGE – late gadolinium enhancement, LVH – left ventricular 
hypertrophy, LVMi – indexed left ventricular mass, MWT – maximum wall 
thickness, NS – non-significant.  
 
  
Table 2a. Mean global longitudinal strain values in various subcohorts of the 
total study population 
 
HV total HV males HV females  Fabry total 
Fabry 
males 
Fabry 
females p 
-19.3±2.0 -18.5±1.8 -20.2±1.9 LVH positive 
(n=102 
-16.4±3.6 -15.5±3.4 -17.8±3.5 <0.05 * 
LVH negative 
(n=119) 
-20.3±2.9 -18.7±1.7 -20.7±2.3 NS ** 
 
*p-value comparing Fabry vs. HV in all groups **p-value comparing Fabry 
males/females vs. HV males/females. 
 
Table 2b. Mean global longitudinal strain values in various subcohorts of the 
LVH negative Fabry population 
 
 Subcohort 1 Subcohort 2 P* 
Normal T1 Low T1 
Fabry total -20.5±1.9 -20.2±2.6 NS 
Fabry males -20.0±1.0 -18.3±1.6 <0.05 
Fabry females -20.6±2.0 -20.9±2.5 NS 
 
 Low T1 + ECG normal 
Low T1  + ECG 
abnormal  
Fabry total -20.4±2.8 -19.9±2.4 NS 
Fabry males -18.1±1.9 -18.9±1.1 NS 
Fabry females -21.2±2.5 -20.3±2.7 NS 
 
*p-value is comparing subcohort 1 vs. subcohort 2 in all groups.   
 
Table legend: HV – healthy volunteers, LVH – left ventricular hypertrophy, ECG – 
electrocardiogram, NS – non-significant.  
 
  
Figure 4. The relationship between global longitudinal strain and native T1 in 
LVH negative Fabry and healthy volunteers.  
 
 
*Indicates p-value <0.05.  
Graph represents the mean peak GLS with standard deviation error bars. Of the LVH 
negative Fabry cohort, there is significant impairment in mean GLS in male patients 
with a low T1 time compared to those with a normal T1 and healthy volunteers.  
 
Figure legend: LVH – left ventricular hypertrophy, GLS – global longitudinal strain.  
  
Supplementary table 1. Correlation between different variables in the total 
population and the LVH negative cohort.  
 
Variables Correlation coefficient (R2) p 
LVMi + MWT 0.9 <0.001 
MWT + LVEF 0.1 <0.05 
MWT + GLS 0.7 <0.01 
LVH negative (n=131)* 
T1 + GLS -0.3 0.03 
*LVH negative classified as MWT 12mm 
 
Table legend: LVMi – indexed left ventricular mass, MWT – maximum wall 
thickness, LVEF – left ventricular ejection fraction, GLS – global longitudinal strain, 
LVH – left ventricular hypertrophy.  
 
Supplementary table 2. Mean GLS in Fabry males and females who are LVH 
negative.  
 
 Low T1 Normal T1 p 
Males -18.6±1.9 -20.0±1.0 0.03* 
Females -20.8±2.5 -20.6±1.9 0.67 
 
Supplementary figure 1. Scatter plot showing the relationship between native T1 
and 2D GLS in the LVH negative cohort.  
 
 
 
LVH negative has been defined as a MWT 12 mm.  
 
  
Supplementary table 3. The relationship of GLS and native T1 with baseline clinical characteristics (linear regression analysis) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table legend: CI – confidence interval, GLS – global longitudinal strain, LVMi – indexed left ventricular mass, LGE – late gadolinium 
enhancement, LVH – left ventricular hypertrophy, ERT – enzyme replacement therapy.  
 
Dependent 
variable 
Independent 
variables 
Uni-variable analysis Multivariable model 
Coefficient 95% CI p R2 Coefficient 95% CI p R2 
Total population (n=221) 
 Age (years) 0.35 0.05-0.11 <0.01 0.12     
GLS (%) LVMi (g/m2) 0.68 0.05-0.07 <0.01 0.46 0.60 0.04 to 0.07 <0.01 0.49 
 LGE 0.36 1.62-3.11 <0.01 0.13 -0.15 -2.04 to 0.08 0.069  
 Male gender 0.35 1.04-1.98 <0.01 0.12     
 Troponin 0.52 1.80-3.11 <0.01 0.27     
 T1 time (ms) -0.47 -0.03-0.18 <0.01 0.22 0.27 -0.02 to 0.006 <0.01  
 LVMi (g/m2) -0.58 -1.20 to -0.86 <0.01 0.34 -0.22 -0.70 to -0.07 0.016 0.35 
T1 time (ms) GLS (%) -0.47 -11.59 to -7.44 <0.01 0.22 -0.27 -8.50 to -1.94 0.002  
 Age (years) -0.35 -2.02 to -9.6 <0.01 0.12 -0.17 -1.29 to -0.17 0.011  
 LGE -0.53 -91.15 to -61.38 <0.01 0.28     
 ERT -0.46 -76.10 to -48.49 <0.01 0.21 -0.13 -32.92 to -0.27 0.046  
LVH negative (n=119) 
 Age (years) -0.15 -0.06 to 0.005 0.096 0.024     
GLS (%) LVMi (g/m2) 0.386 0.05 to 0.12 <0.01 0.15 0.35 0.03 to 0.12 0.001 0.22 
 Male gender 0.34 1.00 to 3.03 <0.01 0.12     
 T1 time (ms) -0.29 -0.02 to -0.01 0.002 0.081 -0.20 -0.17 to 0.00 0.058  
 Troponin 0.17 -0.23 to 2.03 0.118 0.03     
 LVMi (g/m2) -0.40 -2.99 to -1.20 <0.01 0.16 -0.28 -2.48 to -0.52 0.003 0.29 
T1 time (ms) GLS (%) -0.29 -11.10 to -2.64 0.002 0.08 -0.18 -9.14 to -0.52 0.047  
 Age (years) -0.10 -1.18 to 0.33 0.267 0.01 -0.30 -74.53 to -20.76 0.001  
 LGE -0.29 -75.21 to -16.38 0.03 0.09     
 ERT -0.22 -45.58 to-4.33 0.18 0.05 -0.19 -41.0 to -1.89 0.032  
